Oric Pharmaceuticals (ORIC) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 18, 2026, to be held virtually for shareholders of record as of April 20, 2026.

• Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online, with paper copies available upon request.

Voting matters and shareholder proposals

• Election of two Class III directors to serve until the 2029 annual meeting or until successors are qualified.

• Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Approval of the amended and restated 2020 Equity Incentive Plan.

• Advisory vote on executive compensation and on the frequency of future advisory votes, with board recommending an annual vote.

• Provision to transact other business that may properly come before the meeting.

Board of directors and corporate governance

• Board recommends voting for all proposals and for the election of Jacob M. Chacko, M.D. and Mardi C. Dier as Class III directors.